UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ____________ Commission File Number: 001-39323 VAXCYTE, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ____________ Commission File Number: 001-39323 VAXCYTE, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdictio ...

| --- | --- | --- | --- | --- | |---------------------------------------|-------|-------|-------|-------| | | | | | | | 4Q & FY 2022 | | | | | | Financial Results and Business Update | | | | | | | | | | | February 27, 2023 VAXCYTE Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the potential benefits of Vaxcyte's vaccine candidat ...

Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Andrew Guggenhime - President and Chief Financial Officer Grant Pickering - Chief Executive Officer Jim Wassil - Executive Vice President and Chief Operating Officer Jeff Fairman - Vice President, Research Conference Call Participants Jason Gerberry - Bank of America Roger Song - Jefferies David Risinger - SVB Seamus Fernandez - Guggenheim. Jonathan Miller - Evercore Louise Chen - Cantor Joseph Str ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ___________ Commission File Number 001-39323 VAXCYTE, INC. (Exact name of Registrant as specified in its Charter) | Delaware | 46-4233385 | | --- | -- ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ____________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Commission File Number: 001-39323 VAXCYTE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-4233385 (St ...

Corporate Presentation VAXCYTE August 8, 2022 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the potential benefits of Vaxcyte's vaccine candidates, including breadth of coverage and the ability to deliver a potentially best-in-class pneumococcal conjugate vaccine; demand for Vaxcyte's vaccine candidates; the process and timing ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ____________ Commission File Number: 001-39323 VAXCYTE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-4233385 (State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ____________ Commission File Number: 001-39323 VAXCYTE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-4233385 (State ...

Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2021 Earnings Conference Call February 28, 2022 4:30 PM ET Company Participants Andrew Guggenhime - President and CFO Grant Pickering - CEO Jim Wassil - COO Jeff Fairman - VP of Research Conference Call Participants Komal Patel - Bank of America Louise Chen - Cantor Joseph Stringer - Needham & Company Operator Good afternoon. My name is Josh, and I will be your conference operator today. At this time, I would like to welcome everyone to the Vaxcyte Fourth Quarter and Full-Y ...